Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Rodabe N. Amaria"'
Autor:
Omar Pacha, Rodabe N. Amaria, Lauren E. Haydu, Kelly C. Nelson, Isabella C. Glitza Oliva, M. Wong, Shirley Q. Li, Auris Huen, Sahira Farooq, Macartney Welborn, Ronald P. Rapini, Michael A. Davies, Anisha B. Patel, Jennifer L. McQuade, Sapna Pradyuman Patel, Adi Diab, Susan Y. Chon, Hussein Abdul-Hassan Tawbi
Publikováno v:
Cancer. 128:975-983
Background In response to the increased use of combination checkpoint inhibitors (CPIs) and the resulting increased cutaneous adverse events (CAEs), this study reviewed patients with melanoma treated with combination CPIs to characterize CAE features
Autor:
Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos Torres-Cabala, Isabella C. Glitza, Fei Duan, Denái R. Milton, Klaus Busam, Lauren Simpson, Jennifer L. McQuade, Michael K. Wong, Jeffrey E. Gershenwald, Jeffrey E. Lee, Ryan P. Goepfert, Emily Z. Keung, Sarah B. Fisher, Allison Betof-Warner, Alexander N. Shoushtari, Margaret Callahan, Daniel Coit, Edmund K. Bartlett, Danielle Bello, Parisa Momtaz, Courtney Nicholas, Aidi Gu, Xuejun Zhang, Brinda Rao Korivi, Madhavi Patnana, Sapna P. Patel, Adi Diab, Anthony Lucci, Victor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte Ariyan, Hussein A. Tawbi
Publikováno v:
Nature. 611(7934)
Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma1. We investigated this regimen in patients with resectable clinical stage III or oligomet
Autor:
Christian U. Blank, Rodabe N. Amaria, Jennifer A. Wargo, Bart A. van de Wiel, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Alexander C. Huang, Xiaowei Xu, Richard A. Scolyer, Tara C. Mitchell, Giorgos C. Karakousis, Alexander C.J. van Akkooi, Michael A. Davies, Andrew J. Spillane, Elisa A. Rozeman, Alexander M. Menzies, Robyn P. M. Saw, Michael T. Tetzlaff, Ahmad A. Tarhini, Thomas E. Pennington, Elizabeth M. Burton, Paolo A. Ascierto, Serigne Lo
Publikováno v:
Nature Medicine. 27:301-309
The association among pathological response, recurrence-free survival (RFS) and overall survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we pooled data from six clinical trials of anti-PD-1-based immunotherapy or BRA
Autor:
Neil D. Gross, Randal S. Weber, Wen-Jen Hwu, Jeffrey E. Lee, Shaojun Zhang, Courtney W. Hudgens, Vancheswaran Gopalakrishnan, Padmanee Sharma, Alexander J. Lazar, Rodabe N. Amaria, Merrick I. Ross, Amy C. Hessel, Christine N. Spencer, Lauren Simpson, Richard A. Ehlers, Jeffrey E. Gershenwald, Michael A. Davies, Michael K. Wong, Hussein Abdul-Hassan Tawbi, James P. Allison, Liberty Posada, Daniel K. Wells, Robin Kageyama, Sapna Pradyuman Patel, Isabella C. Glitza, Adi Diab, Denái R. Milton, Michael T. Tetzlaff, Richard E. Royal, Scott E. Woodman, Carol M. Lewis, Miles C. Andrews, Alexandre Reuben, Sangeetha M. Reddy, Lauren E. Haydu, Victor G. Prieto, Ehab Y. Hanna, Patrick Hwu, Elizabeth M. Burton, Janice N. Cormier, Jennifer A. Wargo, Anthony Lucci, Stephen Y. Lai, Jorge Blando, Linghua Wang
Publikováno v:
Nature medicine
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses over adjuvant treatment1; however, optimal regimens have not been defined. Herein, we re
Autor:
Lauren E. Haydu, Sapna Pradyuman Patel, Adi Diab, Hussein Abdul-Hassan Tawbi, Michael A. Davies, Suhendan Ekmekcioglu, Jennifer L. McQuade, Isabella C. Glitza, Dai Ogata, Michael K. Wong, Rodabe N. Amaria
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 7, Pp 2293-2299 (2021)
Cancer Medicine, Vol 10, Iss 7, Pp 2293-2299 (2021)
Background Anti‐programmed cell death protein 1 (PD‐1) antibodies are a standard treatment for metastatic melanoma patients. However, the understanding of the efficacy of anti‐PD‐1 for acral melanoma (AM) and mucosal melanoma (MM) is limited
Autor:
Rodabe N. Amaria, Meredith S. Pelster
Publikováno v:
Current treatment options in oncology. 21(2)
Patients with clinical stage III melanoma, defined as palpable lymph nodes with or without in-transit metastases, have poor prognosis even with recent advances with targeted and checkpoint inhibitor therapy in the adjuvant setting. Neoadjuvant therap
Autor:
Michael T. Tetzlaff, Jonathan L. Curry, Phyu P. Aung, Rodabe N. Amaria, Doina Ivan, Priyadharsini Nagarajan, Tsetan Dolkar, Carlos A. Torres-Cabala, Victor G. Prieto, Celestine M Trinidad, Kelly C. Nelson
Publikováno v:
Journal of Cutaneous Pathology. 45:539-544
LL-37 is a naturally occurring 37-amino-acid peptide that is part of the innate immune system in human skin. Preclinical studies have showed that intra-tumoral injections of LL-37 stimulate the innate immune system by activation of plasmacytoid dendr
Autor:
Leon Chen, Marc Uemura, Genie A. Landon, Rodabe N. Amaria, Amir A. Jazaeri, Phyu P. Aung, Carlos A. Torres-Cabala, Adrienne N. Choksi, Priyadharsini Nagarajan, Brinda Rao Korivi, Michael A. Davies, Padmanee Sharma, Michael T. Tetzlaff, Jonathan L. Curry, Victor G. Prieto, Adi Diab
Publikováno v:
Journal of Cutaneous Pathology. 44:1080-1086
Immunotherapies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1) have showed substantial therapeutic benefit in patients with clinically advanced solid malignancies.
Autor:
Jennifer L. McQuade, Michael K.K. Wong, Charlotte E. Ariyan, Hussein Abdul-Hassan Tawbi, Elizabeth M. Burton, Sarah B. Fisher, Michael A. Postow, Sapna Pradyuman Patel, Adi Diab, Emily Z. Keung, Denái R. Milton, Michael A. Davies, Isabella C. Glitza, Jennifer A. Wargo, Rodabe N. Amaria, Merrick I. Ross, Lauren Simpson, Michael T. Tetzlaff, Ryan P. Goepfert, Jeffrey E. Gershenwald
Publikováno v:
Journal of Clinical Oncology. 39:9502-9502
9502 Background: Neoadjuvant therapy (NT) for pts with clinical stage III melanoma remains an active area of research interest. Recent NT trial data demonstrates that achieving a pathologic complete response (pCR) correlates with improved relapse-fre
Autor:
Michael K.K. Wong, Michael A. Davies, Denái R. Milton, Sapna Pradyuman Patel, Adi Diab, Virginia Honaker, Patrick Hwu, Isabella C. Glitza, Rodabe N. Amaria, Jennifer L. McQuade, Jennifer A. Wargo, Hussein Abdul-Hassan Tawbi, Elizabeth M. Burton
Publikováno v:
Journal of Clinical Oncology. 39:9520-9520
9520 Background: Targeted therapies (TT) & immunotherapies (IMT) have improved survival for pts with BRAF V600 mutated stage IV MM, however many pts still progress and ultimately die from their disease. Preclinical data support the rationale for comb